2025-12-17 - Analysis Report
Here's a breakdown of SDGR (Schrodinger Inc.) based on the provided data:

**0. Introduction**

Schrodinger Inc. (SDGR) is a company focused on developing software for drug discovery and materials science.

**1. Return Rate Comparison**

*   **SDGR Cumulative Return:** -55.26%
*   **S&P 500 (VOO) Cumulative Return:** 67.97%
*   **Divergence:** -125.8 (Relative Divergence: 0.8)

**Analysis:** SDGR has significantly underperformed the S&P 500 over the period for which cumulative return data is available. The large negative divergence indicates a substantial difference in returns. The relative divergence of 0.8 suggests that the current divergence is near the minimum level of observed fluctuation, but still reflecting underperformance.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2020-2022  | -70.0% | 78.2% | -76.0% | 0.0 | 1.4 |
| 2021-2023  | -57.0% | 81.0% | -59.0% | -0.0 | 2.6 |
| 2022-2024  | 6.0% | 81.0% | -14.0% | -0.0 | 1.4 |
| 2023-2025  | -4.0% | 82.6% | -68.0% | -0.0 | 1.3 |

*   **CAGR:** The Compound Annual Growth Rate is negative in most periods, indicating a decline in value over these timeframes, except for 2022-2024.
*   **MDD:** The Maximum Drawdown is high (78.2% - 82.6%), indicating significant risk and volatility.
*   **Alpha:** The negative alpha indicates underperformance relative to its benchmark.
*   **Beta:** Beta is approximately 0.0 in all periods, implying that it is very stable compared to market.
*   **Cap(B):** Market Capitalization in Billions.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** $17.94
*   **Previous Close:** $18.21
*   **Change:** -1.48%
*   **5-day SMA:** $18.05
*   **20-day SMA:** $17.47
*   **60-day SMA:** $19.12

**Analysis:** The current price is below the 5-day and 60-day SMAs but above the 20-day SMA. The recent price decrease suggests a short-term downtrend, though the price hovers in the general vicinity.

**3. Index Indicators & Expected Return**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 60.25
*   **PPO:** 0.9871
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (58 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** -0.3 (Short-term Decrease)
*   **Expected Return:** -6470.0%

**Analysis:**

*   The MRI suggests a medium level of investment risk, indicating that while it is not extremely risky, it is not a low-risk investment either.
*   The RSI is approaching overbought, though at 60 it does not qualify.
*   The negative change in relative divergence suggests recent underperformance compared to the market.
*   The dramatically negative expected return is highly concerning, suggesting significant potential for further losses if held long-term.

**4. Recent News & Significant Events**

*   **Positive Sentiment:** Several articles highlight potential value and upgrades by analysts (B of A Securities).
*   **Analyst Target:** Quiver Quantitative reports a $24 price target from a new analyst forecast.
*   **Institutional Investment:** Nikko Asset Management Americas Inc. purchased shares.

**Analysis:** Recent news presents a mixed picture. Positive analyst ratings and institutional investment suggest potential upside. However, investors should conduct thorough research to determine if these are isolated opinions.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.44)
*   **Target Price:** Average $27.22 (High: $33, Low: $18)

**Analysis:** Analyst consensus is positive, with a strong buy rating and an average target price significantly above the current price. This suggests analysts believe the stock is undervalued.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | -0.45 | 0.05 B$   |
| 2025-08-06 | -0.59 | 0.05 B$   |
| 2025-05-07 | -0.82 | 0.06 B$   |
| 2024-11-12 | -0.52 | 0.04 B$   |
| 2025-11-05 | -0.52 | 0.04 B$   |

**Analysis:** The company is consistently reporting negative EPS (Earnings Per Share), which is a concern. Revenue has fluctuated but has not shown consistent growth.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30 | $0.05B  | 51.61%        |
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |

**Capital and Profitability**

| Quarter      | Equity | ROE       |
|--------------|--------|-----------|
| 2025-09-30 | $0.32B | -10.21%   |
| 2025-06-30 | $0.34B | -12.59%   |
| 2025-03-31 | $0.37B | -16.01%   |
| 2024-12-31 | $0.42B | -9.54%    |
| 2024-09-30 | $0.45B | -8.49%    |

**Analysis:**

*   Revenue is relatively stable. Profit margins are positive.
*   Equity is decreasing, and ROE (Return on Equity) is negative, reflecting the losses the company is incurring.

**7. Comprehensive Analysis**

SDGR presents a mixed investment picture:

*   **Negatives:** The stock has significantly underperformed the S&P 500. It shows high volatility (MDD), and negative earnings. The dramatically negative expected return is a major cause for concern.
*   **Positives:** Analyst consensus is "Strong Buy" with a significantly higher price target, and recent news indicates analyst upgrades and institutional investment. Revenue and profit margins are positive. The MRI is currently at a moderate level.

**Overall:**

SDGR is a high-risk, high-reward investment. The company faces significant challenges in profitability and growth, reflected in its negative earnings and historical underperformance. However, analyst optimism, recent upgrades, and institutional interest suggest potential for a turnaround. *Investors should carefully weigh the risks and potential rewards before investing in SDGR.* A key factor to monitor is the company's ability to improve its financial performance and achieve profitability.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.